Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Dr. Jahanzeb on the Future of Adjuvant Therapy in HER2+ Breast Cancer

March 22nd 2017

Mohammad Jahanzeb, MD, professor of Clinical Medicine, Hematology/Oncology, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the future of adjuvant treatment in HER2-positive breast cancer.

Dr. Tripathy on Standard and Emerging Treatment Advances for HER2+ Breast Cancer

March 22nd 2017

Debu Tripathy, MD, chair of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses standard and emerging advances in the treatment of patients with HER2-positive breast cancer.

Dr. Carey on Tailoring Treatment in Triple-Negative Breast Cancer

March 20th 2017

Lisa A. Carey, MD, professor, UNC Lineberger Comprehensive Cancer Center, discusses tailoring treatment for patients with triple-negative breast cancer (TNBC).

Abemaciclib Improves PFS in Phase III Breast Cancer Trial

March 20th 2017

In the phase III MONARCH 2 study, adding abemaciclib to fulvestrant improved progression-free survival compared with fulvestrant alone in women with hormone receptor-positive/HER2-negative breast cancer.

Dr. Janni on Reducing Adverse Events of HER2-Targeted Treatment in Breast Cancer

March 19th 2017

Wolfgang Janni, MD, PhD, University of Ulm, disucusses the management of adverse events in HER2-targeted therapies.

Dr. Curigliano Discusses Immunotherapy in Breast Cancer

March 19th 2017

Giuseppe Curigliano, MD, PhD, head of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, discusses the emergence of immunotherapy in breast cancer.

Neoadjuvant Therapy Fundamental in TNBC and HER2+ Breast Cancer

March 19th 2017

Neoadjuvant therapy in early breast cancer has evolved during the past 2 decades from use primarily in large inoperable tumors to a standard treatment option for patients with early-stage HER2-positive and triple-negative breast cancer.

Age, Subtype Impact Outcomes More Than Surgical Extent in Breast Cancer

March 18th 2017

Age and the molecular subtype were more closely associated with long-term outcomes compared with the use of either breast-conserving surgery or mastectomy for patients with breast cancer.

Expert Examines Clues to Deploying Immunotherapy in Breast Cancer

March 18th 2017

Immunotherapy will be most effective as a treatment for breast cancer when it is used to alter the tumor microenvironment, according to a careful examination of studies exploring the immune response presented by Nora Disis, MD.

CDK4/6 Inhibitors Changing Practice in Advanced Breast Cancer

March 17th 2017

Inhibition of CDK4/6 results in improvements in progression-free survival in women with estrogen receptor-positive/HER2-negative metastatic breast cancer whether it is endocrine sensitive or resistant.

Expert Discusses Promise of Immunotherapy in TNBC

March 17th 2017

Giuseppe Curigliano, MD, PhD, discusses recent trials of immunotherapy and chemotherapy in triple-negative breast cancer, as well as the future role of immunotherapy in the treatment of breast cancer.

Dr. Hayes Discusses Tumor Biomarker Tests in Breast Cancer

March 17th 2017

Daniel F. Hayes, MD, professor University of Michigan Comprehensive Cancer Center, discusses the use of tumor biomarker tests in breast cancer.

Dr. Piccart on the Importance of De-Escalation in Early Breast Cancer

March 17th 2017

Martine J. Piccart, MD, PhD, professor, Université Libre de Bruxelles, director, Medicine Department, Institut Jules Bordet, discusses the importance of de-escalating treatment in early-stage breast cancer.

Combination Approaches Combat Resistance to Endocrine Therapy in HR+ Breast Cancer

March 17th 2017

Genomic studies have made significant advancements in discovering methods to combat resistance to endocrine therapy in patients with hormone receptor (HR)–positive breast cancer over the past few years, according to Ian E. Krop, MD, PhD. Of particular interest are combination therapies blocking multiple driver pathways and resistance mechanisms.

Ribociclib Response Unaffected by Prior Treatment

March 17th 2017

Updated findings from the MONALEESA-2 trial demonstrated that the response to ribociclib (Kisqali) in postmenopausal women with hormone-receptor-positive/HER2-negative advanced or metastatic breast cancer was unaffected by either prior endocrine treatment or prior chemotherapy.

Combinations Show Promise in Overcoming Resistance to HER2-Targeting Therapy

March 16th 2017

C. Kent Osborne, MD, discusses current strategies for overcoming resistance to HER2-targeting agents in early breast cancer today.

Dr. Ellis on Potential Impact of CDK4/6 Inhibitors in Breast Cancer

March 16th 2017

Matthew Ellis, MD, PhD, director, Smith Breast Center, Baylor College of Medicine, discusses questions regarding the impact of CDK4/6 inhibitors in breast cancer.

Dr. Osborne Discusses the Future of Treatment in HER2+ Breast Cancer

March 16th 2017

C. Kent Osborne, MD, director, Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, discusses the death of chemotherapy and rise of targeted agents in the treatment of patients with HER2-positive breast cancer.

Sexual Health Counseling Should Be Paired With AI Breast Cancer Treatment

March 15th 2017

Preventive sexual counseling can be effective in reducing sexual dysfunction resulting from the treatment of breast cancer patients with aromatase inhibitors; however, that intervention should be provided early in treatment and supported by encouragement from providers.

Neoadjuvant Therapy Improves Breast Conservation Outlook

March 15th 2017

Debu Tripathy, MD, provided an update on neoadjuvant strategies in HER2-positive breast cancer at the 2017 Miami Breast Cancer Conference.